Drug
Tifcemalimab clinical trials
Also written JS004 and TAB004.
- studies test it
- 13
- open now
- 7
- in phase 3
- 1
- first study started
- 2019
Keep track of what changes. Save the tifcemalimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
13 studies that test it; most in 2024 (5)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 5 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 8
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 12
Shanghai Junshi Bioscience Co., Ltd. (5) · Shanghai Pulmonary Hospital, Shanghai, China (3) · Fudan University (2) · Henan Provincial People's Hospital (1) · TopAlliance Biosciences (1) · Sichuan University (1)
Often tested with
Tested in the same studies.
Toripalimab (7) · JS007 (1) · Anti-DKK1 Monoclonal Antibody JS015 (1) · Irinotecan sucrosofate (1) · Fluorouracil (1) · Leucovorin (1) · Albumin-Bound Paclitaxel (1) · Paclitaxel (1)
Studies
Open first, then newest update. How each study uses tifcemalimab is read from its arms, and is right about nine times in ten.
Testing it · 13
- Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)RecruitingPhase 3Shanghai Junshi Bioscience Co., Ltd.NCT06095583Written as Tifcemalimab injection
- Combination of Toripalimab and JS004 Therapy for ccRCCRecruitingPhase 2Fudan UniversityNCT06690697Written as JS004
- BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaNot yet recruitingPhase 2Henan Provincial People's HospitalNCT06588335Written as BTLA inhibitor (JS004)
- Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 TrialRecruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT06256237Written as JS004
- Newly Emerging Immunotherapy for Pancreatic Cancer TreatmentNot yet recruitingPhase 1/2Fudan UniversityNCT06370754Written as JS004
- Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced MalignanciesRecruitingPhase 1TopAlliance BiosciencesNCT04137900Written as TAB004
- Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 TrialNot yet recruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT05891080Written as JS004
- Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung CancerCompletedPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT06648200Written as JS004
- Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and ImmunotherapyTerminatedPhase 2Shanghai Junshi Bioscience Co., Ltd.NCT06924606Written as JS207 injection +JS004 injection
- Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLCWithdrawnPhase 1Sichuan UniversityNCT06732258Written as Tifcemalimab injection
- A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid TumorsTerminatedPhase 1Shanghai Junshi Bioscience Co., Ltd.NCT05427396Written as JS004
- Safety, Tolerability and Pharmacokinetics of a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced MalignanciesCompletedPhase 1Shanghai Junshi Bioscience Co., Ltd.NCT04278859Written as Drug: JS004, Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection Intravenous infusion
- The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNCCompletedPhase 1/2Shanghai Junshi Bioscience Co., Ltd.NCT04929080Written as JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
Given in every arm · 2 — tifcemalimab is usual care beside what is tested
- JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung CancerCompletedPhase 1/2Shanghai Junshi Bioscience Co., Ltd.NCT05664971Written as Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection
- A Phase I Clinical Study of JS004 in Subjects With Recurrent/Refractory Malignant Lymphoma of ChinaCompletedPhase 1Shanghai Junshi Bioscience Co., Ltd.NCT04477772Written as JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
Codes
What other systems call tifcemalimab · ClinicalTrials.gg INT016278
- UNII (FDA) D40H7X1YZ0TIFCEMALIMABOne source FDA
- NCI Thesaurus C168617TifcemalimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | D40H7X1YZ0 | TIFCEMALIMAB | One source FDA |
| NCI Thesaurus | C168617 | Tifcemalimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.